Inki Lee
Seoul, 139706, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Cutoff SUVR of [18F]Florapronol PET for Differentiating Alzheimer's Dementia from Normal Controls: Insights from ROC Analysis and Partial Volume Correction.
Journal: Nuclear medicine and molecular imaging
Published: November 20, 2024
F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study.
Journal: Nuclear medicine and molecular imaging
Published: October 18, 2024
18F-FDOPA PET/CT in Oncology: Procedural Guideline by the Korean Society of Nuclear Medicine.
Journal: Nuclear medicine and molecular imaging
Published: October 02, 2024
Evaluating 64 Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18 F-fluorodeoxyglucose PET/computed tomography.
Journal: Nuclear medicine communications
Published: August 19, 2024
Deep learning-based organ-wise dosimetry of 64Cu-DOTA-rituximab through only one scanning.
Journal: Scientific reports
Published: September 28, 2023
A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.
Journal: Clinical Medicine Insights. Oncology
Published: August 30, 2023
Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer.
Journal: Diagnostics (Basel, Switzerland)
Published: July 05, 2023
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831.
Journal: Pediatric blood & cancer
Published: January 11, 2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.
Journal: British journal of haematology
Published: January 05, 2023
Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.
Journal: Asia-Pacific journal of clinical oncology
Published: November 02, 2022
64 Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression.
Journal: Clinical nuclear medicine
Published: September 21, 2022
The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.
Journal: Journal of breast cancer
Published: October 12, 2021
Last Updated: 09/26/2026